Victor Perlroth, Kodiak Sciences CEO
November 6, 2023 02:01 PM EST
R&D

Ko­di­ak 're­boot­s' Eylea com­peti­tor af­ter pos­i­tive da­ta in di­a­bet­ic vi­sion loss tri­al

Katherine Lewin

News Reporter

De­spite two failed late-stage tri­als, Pa­lo Al­to-based biotech Ko­di­ak Sci­ences said it’s go­ing to restart de­vel­op­ment of its po­ten­tial Eylea ri­val …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times